AbbVie Inc. Stock Performance
AbbVie Inc. shares closed at $264.40, reflecting a single-session decline of 1.32% per SID market data. Despite the daily pullback, the stock has demonstrated consistent upward momentum across multiple timeframes, gaining 0.55% over the past month, 4.34% over three months, and 17.85% over the trailing twelve months. The stock currently trades above both key moving averages, sitting 2.86% above its 50-day moving average of $257.05 and 14.47% above its 200-day moving average of $230.99, according to SID market data. The 14-day relative strength index registers at 65.0, indicating bullish momentum without entering overbought territory. AbbVie maintains a notably low beta of 0.334, suggesting significantly reduced volatility relative to the broader market. Average daily trading volume stands at approximately 6.4 million shares, supporting a total market capitalization of roughly $410 billion, positioning AbbVie among the largest companies in the Healthcare sector.
AbbVie Inc. Valuation Analysis
AbbVie Inc. currently trades at a price-to-earnings ratio of 97.75, a notably elevated multiple that reflects the impact of significant amortization charges and acquisition-related expenses on reported GAAP earnings, per SID market data. The PEG ratio stands at 1.25, suggesting the stock's valuation is more reasonable when factored against projected earnings growth. The company's price-to-book ratio registers as negative at -126.33, a consequence of AbbVie's negative book value driven by substantial goodwill impairments and accumulated debt from its 2020 Allergan acquisition, according to SEC filings. AbbVie offers a forward dividend yield of 2.87%, providing meaningful income for shareholders in the Healthcare sector. The company's $410 billion market capitalization reflects investor confidence in its diversified immunology and oncology portfolio. These valuation metrics underscore the importance of evaluating AbbVie on an adjusted earnings basis rather than relying solely on GAAP-derived multiples.
Smart Money Activity for ABBV
AbbVie Inc. registers a smart money composite score of 56 with a neutral overall signal, according to SID market data. The institutional component scores a perfect 25 out of 25, indicating exceptionally strong conviction from large asset managers and mutual funds holding ABBV shares. The insider trading component also scores favorably at 18 out of 25, supported by two insider transactions recorded over the past 90 days, per SEC Form 4 filings. Notably, both transactions were purchases with zero insider sales during the period, signaling management confidence in AbbVie's forward trajectory. The dark pool activity score stands at 9.5 out of 25, reflecting moderate levels of off-exchange institutional trading. Congressional trading activity remains minimal, scoring just 3.2 out of 25, indicating limited disclosed trading by members of Congress, per 13F institutional filings. The divergence between strong institutional ownership and modest dark pool activity suggests established long-term holders are maintaining positions rather than actively accumulating or distributing shares.
AbbVie Inc. Earnings Outlook
AbbVie Inc. has delivered mixed earnings results across recent quarters, according to company earnings reports. In the most recent reported quarter, AbbVie posted earnings per share of $2.65 against a consensus estimate of $2.66, resulting in a marginal miss of $0.01. The prior quarter saw stronger execution, with actual EPS of $2.71 surpassing the $2.66 estimate by $0.05. However, the earliest available quarter showed a more significant shortfall, with actual EPS of $3.65 falling $0.12 below the $3.77 consensus expectation, per analyst estimates. Looking ahead, analysts project EPS of $3.01 for the upcoming reporting period scheduled for April 24, 2026. The pattern of narrow earnings variances reflects AbbVie's relatively predictable revenue streams from key franchises including Skyrizi and Rinvoq, which have been absorbing the revenue decline from Humira's biosimilar competition. Investors will monitor whether the company can return to consistent beats in subsequent quarters.
Wall Street Analyst Ratings for ABBV
Wall Street consensus on AbbVie Inc. remains predominantly constructive, with recent analyst actions skewing bullish, per Wall Street analyst reports. HSBC reiterated a Buy rating on September 10, 2026, while Piper Sandler maintained its Overweight rating on August 20 and Wells Fargo reaffirmed Overweight on August 17. The most notable upgrade came from Wolfe Research on August 13, which elevated ABBV from Peer Perform to Outperform, signaling increased confidence in the company's growth trajectory. BNP Paribas maintained a Neutral stance on August 11, representing the sole non-bullish view among recent coverage updates, according to SID consensus data. Of the five most recent analyst actions, four carry bullish or outright buy-equivalent ratings, while only one holds a neutral position. The Wolfe Research upgrade is particularly significant as it reflects a directional change in sentiment rather than a simple reiteration. No analyst has issued a sell-equivalent rating on ABBV in the reviewed period, underscoring broad institutional confidence.
